Core Viewpoint - The Hang Seng Index Company announced the quarterly review results for the Hang Seng Index series, with Health 160 (02656) being included in the Hang Seng Composite Index, effective March 9, 2026 [1] Group 1: Company Overview - Health 160 is an experienced Chinese pharmaceutical and health products wholesaler and a leading provider of integrated digital healthcare services [1] - The company offers a variety of pharmaceutical health products and comprehensive digital healthcare solutions [1] - Health 160 operates an online healthcare service platform that connects various participants in the healthcare industry [1] Group 2: Market Impact - The inclusion of Health 160 in the Hang Seng Composite Index may lead to its potential addition to the Stock Connect program, as it meets criteria such as market capitalization, liquidity, and listing duration [1] - As of March 31, 2025, Health 160's platform has connected over 44,600 healthcare institutions since its establishment [1]

Core Viewpoint - The Hang Seng Index Company announced the inclusion of Health 160 (02656) in the Hang Seng Composite Index, effective March 9, 2026, following a quarterly review [1] Group 1: Company Overview - Health 160 is an experienced wholesaler of Chinese pharmaceutical and health products, as well as a leading provider of integrated digital healthcare services [1] - The company offers a variety of pharmaceutical health products and comprehensive digital healthcare solutions [1] - Health 160 operates an online healthcare service platform that connects various participants in the healthcare industry, having connected over 44,600 healthcare institutions since its establishment [1] Group 2: Market Impact - The inclusion of Health 160 in the Hang Seng Composite Index may lead to its potential addition to the Stock Connect program, as it meets criteria such as market capitalization, liquidity, and listing duration [1]

Core Viewpoint - Health 160 (02656) experienced a significant decline of nearly 40%, retracting most of its gains for the year, with its market capitalization briefly falling below HKD 20 billion [1] Group 1: Company Overview - Health 160 is an experienced wholesale distributor of pharmaceutical and health products in China and a leading provider of integrated digital healthcare services [1] - The company offers a variety of pharmaceutical health products and comprehensive digital healthcare solutions [1] Group 2: Market Performance - As of the latest report, Health 160's stock price dropped by 32.1%, trading at HKD 61.65, with a trading volume of HKD 32.83 million [1] - The company went public on September 17, 2025, and is facing a significant unlock of restricted shares, with 267 million shares (79% of the circulating shares) set to be released on the same date [1]

Core Viewpoint - Health 160 (02656) experienced a significant decline of nearly 40%, retracting most of its gains for the year, with its market capitalization briefly falling below HKD 20 billion [1] Company Overview - Health 160 is an experienced wholesale distributor of pharmaceutical and health products in China and a leading provider of integrated digital healthcare services [1] - The company offers a variety of pharmaceutical health products and comprehensive digital health solutions [1] - As of March 31, 2025, Health 160's platform has connected over 44,600 healthcare institutions, including more than 14,400 hospitals and over 30,200 grassroots healthcare institutions [1] Market Activity - Health 160 was listed on September 17, 2025 [1] - According to previous reports, companies with high lock-up release market values may face stock price pressure before and after the release [1] - Health 160 is set to unlock 267 million shares on September 17, which represents 79% of its circulating shares [1]

Core Viewpoint - Health 160 is positioned as a leading digital healthcare service platform in China, showing clear signs of a performance turnaround with revenue growth and significantly reduced net losses, indicating a path to profitability [1][2]. Group 1: Financial Performance and Projections - Health 160's revenue is projected to grow from 6.58 billion to 11.49 billion CNY from 2025 to 2027, with growth rates of 6.00%, 21.80%, and 44.12% respectively [2]. - The company is expected to achieve net profits of -0.39 billion, 0.64 billion, and 2.58 billion CNY for the years 2025, 2026, and 2027, respectively, with a forecasted turnaround to profitability in 2026 [2]. Group 2: Business Model and Competitive Advantage - Health 160 operates on a dual-driven model of pharmaceutical distribution and digital health services, with the latter contributing higher profit margins (over 70%) despite a lower revenue share (approximately 30%) [4]. - The platform connects over 44,600 healthcare institutions, including more than 14,400 hospitals, and has established partnerships with over 900,000 healthcare professionals, creating a strong competitive barrier [4]. Group 3: Industry Trends and Growth Potential - The digital healthcare sector in China is experiencing rapid growth, with the market size expected to increase from 548 billion to 2,203 billion CNY, reflecting a compound annual growth rate (CAGR) of 32.1% [5]. - By 2030, the digital health service market is projected to reach 7,401 billion CNY, indicating significant growth potential for leading companies like Health 160 [5]. Group 4: Investment Value and Strategic Outlook - Health 160's investment value is driven by its unique resource and user base advantages, creating a strong network effect that is difficult to replicate [6]. - The company is expected to achieve full profitability by 2026, supported by the growth of high-margin AI medical and digital services [6]. - Future strategic initiatives may include expanding healthcare resource coverage, enhancing research capabilities, and exploring value-added services like commercial health insurance [6].

Core Viewpoint - Health 160 (02656) has seen a significant stock price increase of over 343% since its IPO, reaching a new high of 52.8 HKD, compared to its initial offering price of 11.89 HKD [1] Company Overview - Health 160 is an experienced wholesale distributor of pharmaceutical and health products in China, as well as a leading provider of integrated digital healthcare services [1] - The company offers a wide range of pharmaceutical health products and comprehensive digital healthcare solutions [1] Market Performance - As of the latest report, Health 160's stock is up 6.14%, trading at 52.75 HKD with a transaction volume of 31.5488 million HKD [1] Operational Metrics - Since its establishment, Health 160 has connected with over 44,600 healthcare institutions, including more than 14,400 hospitals (of which 3,430 are tertiary hospitals) and over 30,200 grassroots healthcare institutions, as of March 31, 2025 [1]

Core Viewpoint - Health 160 (02656) has seen a significant increase in stock price, rising over 230% from its IPO price of 11.89 HKD to a peak of 39.5 HKD, indicating strong market interest and performance [1] Company Overview - Health 160 is an experienced wholesaler of pharmaceutical and health products in China, as well as a leading provider of integrated digital healthcare services [1] - The company offers a wide range of pharmaceutical health products and comprehensive digital healthcare solutions [1] - Health 160 operates an online healthcare service platform, connecting various stakeholders in the healthcare industry [1] Platform Connectivity - As of March 31, 2025, Health 160's platform has connected over 44,600 healthcare institutions since its inception [1]

Core Viewpoint - Health 160 (02656) has seen a significant increase in stock price, rising over 230% from its IPO price of 11.89 HKD to a peak of 39.5 HKD, indicating strong market interest and performance [1] Company Overview - Health 160 is an experienced wholesale distributor of pharmaceutical and health products in China, as well as a leading provider of integrated digital healthcare services [1] - The company offers a wide range of pharmaceutical health products and comprehensive digital healthcare solutions [1] - Health 160 operates an online healthcare service platform, connecting various stakeholders in the healthcare industry [1] Platform Connectivity - As of March 31, 2025, Health 160's platform has connected over 44,600 healthcare institutions since its inception [1]

Core Viewpoint - Health 160 (02656) has seen a significant stock price increase, rising over 10% to reach a new high of 35 HKD, nearly doubling from its IPO price of 11.89 HKD [1] Company Overview - Health 160 is an experienced Chinese pharmaceutical and health products wholesaler and a leading provider of digital healthcare integrated services [1] - The company offers a variety of pharmaceutical health products and comprehensive digital healthcare solutions [1] - Health 160 operates an online healthcare service platform, connecting various stakeholders in the healthcare industry [1] Platform Connectivity - As of March 31, 2025, Health 160's platform has connected over 44,600 healthcare institutions since its inception [1] - This includes more than 14,400 hospitals, of which 3,430 are tertiary hospitals, and over 30,200 grassroots healthcare institutions [1]

Core Viewpoint - Health 160 International Limited (Health 160) has successfully listed on the Hong Kong Stock Exchange, with a closing price of 28.22 HKD, reflecting a significant increase of 137.34% from its opening price of 29.98 HKD. The company operates as a wholesaler of pharmaceutical health products and a provider of digital healthcare solutions in China [1]. Group 1: IPO Details - Health 160 issued a total of 33,645,500 shares in its global offering, with 3,364,750 shares allocated for the Hong Kong public offering and 30,280,750 shares for international offering [2]. - The final offer price for the shares was set at 11.89 HKD, resulting in total proceeds of 400 million HKD. After deducting estimated listing expenses of 83.9 million HKD, the net proceeds amounted to 316.1 million HKD [3]. Group 2: Use of Proceeds - The net proceeds from the global offering are intended to be used for expanding healthcare resource coverage, enhancing research and development capabilities, diversifying product and service offerings, exploring strategic partnerships and acquisitions, and for general working capital purposes [3]. Group 3: Financial Performance - Health 160 reported revenues of 525.6 million RMB, 628.6 million RMB, and 620.7 million RMB for the years 2022, 2023, and 2024 respectively, with quarterly revenues of 94.2 million RMB and 100.5 million RMB for the first quarters of 2024 and 2025 [5]. - Despite revenue growth, the company recorded operating losses of 79.2 million RMB, 99.5 million RMB, and 104.6 million RMB for the years 2022, 2023, and 2024, respectively, indicating ongoing challenges in achieving profitability [6]. - The adjusted net losses for the same periods were 118.9 million RMB, 111.2 million RMB, and 108.2 million RMB, with quarterly adjusted net losses of 40.6 million RMB and 17.1 million RMB for the first quarters of 2024 and 2025 [7].